Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.

Also called NCT01613729

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
D16 Pharma & Biotec Ltd. (from the registry)
Registry
  • NCT NCT01613729
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Bangladesh (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01613729. Randomized; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin
Acronym
Cor16
Condition
Dyslipidemia
Intervention (Drug)
Rosuvastatin 5 mg
Intervention (Drug)
Rosuvastatin 10 mg
Lead sponsor
D16 Pharma & Biotec Ltd. (class: industry)
Collaborator
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (class: other)
Collaborator
Dhaka Medical College (class: other)
Collaborator
National Institute of Cardiovascular Diseases (class: not stated)

Record details

Record id
cardio:ct-nct01613729
Content hash
728300aae1d375876831ac30e0b1e22a445a4a97eb7a878b8f632e32d9c9f505